Skip to main content

BellaSeno

MaterialsLeipzig, GermanyFounded 2017· One of 961 Materials companies tracked by AMPulse

BellaSeno develops absorbable, implantable scaffolds that promote natural tissue regeneration, reducing the need for permanent implants and associated complications.

CEO / Founder
Dr. Mohit P. Chhaya
Team Size
11-50
Stage
Active
Total Funding
$4.7M
Latest Round
Grant
Key Investors
Saxony Development Bank (SAB), European Fund for Regional Development (EFRE), Germany's Federal Ministry of Education and Research (BMBF), Australian government

Technology & Products

Key Products

BellaSeno develops next-generation fully absorbable breast scaffolds for breast reconstruction, augmentation, and revision surgeries. They focus on resorbable implants using biomimetic design and AI-driven additive manufacturing.

Technological Advantage

Proprietary scaffold formulations that enhance biocompatibility and reduce complications associated with permanent implants.

Differentiation

Value Proposition

Offers biocompatible and biodegradable absorbable scaffolds that integrate with the body's natural tissue to promote regeneration.

How They Differentiate

BellaSeno differentiates itself through its absorbable scaffold technology as opposed to permanent implants, offering a regenerative solution that integrates with natural tissue.

Market & Competition

Target Customers

Medical professionals, hospitals, and patients in need of breast reconstruction or other soft tissue repair procedures

Industry Verticals

["Medical Devices","Tissue Engineering","Regenerative Medicine"]

Competitors

In the broader breast implant market: Abbvie, Establishment Labs, GC Aesthetics, Mentor Worldwide LLC. In bioresorbable implants and breast reconstruction devices: 4D Biomaterials, Lattice Medical, Healshape, BioAesthetics.

Growth & Milestones

Growth Metrics

Completion of significant clinical trials indicating progress towards commercialization

Major Milestones

["Completion of two significant clinical trials","Positive one-year patient follow-up data for resorbable breast and pectus excavatum scaffolds"]

Notable Customers

BellaSeno is a clinical-stage company. They have partnered with Evonik for commercialization and used SimScale for design optimization. They are also conducting clinical trials.

https://www.bellaseno.com

Why this company matters

BellaSeno occupies a niche at the intersection of additive manufacturing and regenerative medicine, producing absorbable scaffolds designed to be replaced by the patient's own tissue over time. This contrasts with permanent silicone or saline implants, which carry long-term risks of capsular contracture, rupture, or revision surgery. The company's approach targets a clinical gap in breast reconstruction, augmentation, and revision, as well as chest wall deformities such as pectus excavatum.

The core technology uses polymer material extrusion (MEX) to fabricate scaffolds from proprietary biocompatible, biodegradable formulations. These scaffolds are designed with biomimetic architecture intended to support cell infiltration and vascularization. BellaSeno also applies AI-driven design optimization to tailor scaffold geometry to individual patient anatomy, and has used SimScale for simulation-based design validation. The Senella platform is the company's branded scaffold system for breast applications.

BellaSeno is a clinical-stage company. It has completed two clinical trials and reported positive one-year follow-up data for its resorbable breast and pectus excavatum scaffolds. The company partners with Evonik for materials and commercialization support, and has received funding from the Saxony Development Bank, the European Fund for Regional Development, the German Federal Ministry of Education and Research, and the Australian government. Its target customers include hospitals and surgeons performing breast reconstruction or soft tissue repair.

The company's primary differentiator is its fully absorbable scaffold technology, which eliminates the need for permanent hardware. However, it faces competition from other bioresorbable implant developers such as Lattice Medical, Healshape, and 4D Biomaterials, as well as from established permanent implant manufacturers like Abbvie and Establishment Labs. Key open questions include the scalability of its manufacturing process, the long-term mechanical performance of its scaffolds during degradation, and its ability to navigate EU medical device regulations for market entry.